These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7093103)

  • 21. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects.
    Aronoff GR
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S974-6. PubMed ID: 6085387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Butofilolol pharmacokinetics in chronic renal insufficiency.
    Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
    Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
    Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients.
    Chung M; Leitz FH; Maier G; Patrick JE; Gural RP; Symchowicz S
    J Clin Pharmacol; 1986 Apr; 26(4):248-52. PubMed ID: 3700682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Labetalol.
    Carter BL
    Drug Intell Clin Pharm; 1983 Oct; 17(10):704-12. PubMed ID: 6354658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-dose kinetics and dosage of mecillinam in renal failure and haemodialysis.
    Schapira A
    Clin Pharmacokinet; 1984; 9(4):364-70. PubMed ID: 6088153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teicoplanin pharmacokinetics in patients with chronic renal failure.
    Bonati M; Traina GL; Villa G; Salvadeo A; Gentile MG; Fellin G; Rosina R; Cavenaghi L; Buniva G
    Clin Pharmacokinet; 1987 Apr; 12(4):292-301. PubMed ID: 2954735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impaired patients.
    Pechère JC; Pechère MM; Dugal R
    Antimicrob Agents Chemother; 1976 May; 9(5):761-5. PubMed ID: 986124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
    Fillastre JP; Humbert G; Leroy A; Godin M
    Presse Med; 1984 Mar; 13(13):797-801. PubMed ID: 6231597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High pressure liquid chromatography on labetalol in serum or plasma.
    Woodman TF; Johnson B
    Ther Drug Monit; 1981; 3(4):371-5. PubMed ID: 7336471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension.
    Rasmussen S; Nielsen PE
    Br J Clin Pharmacol; 1981 Sep; 12(3):349-53. PubMed ID: 7295465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doses of antibiotic in patients with renal insufficiency.
    Ohkawa M; Kuroda K
    Clin Ther; 1981; 4 Suppl A():124-32. PubMed ID: 6275994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and pharmacokinetic studies on the alpha- and beta-blocking drug labetalol.
    Kanto J; Allonen H; Lehtonen A; Mäntylä R; Pakkanen A
    Ther Drug Monit; 1980; 2(2):145. PubMed ID: 7052285
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability of labetalol in patients with end-stage renal disease.
    Luke DR; Awni WM; Halstenson CE; Opsahl JA; Matzke GR
    Ther Drug Monit; 1992 Jun; 14(3):203-8. PubMed ID: 1412606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of aztreonam in patients with chronic renal failure.
    Fillastre JP; Leroy A; Baudoin C; Humbert G; Swabb EA; Vertucci C; Godin M
    Clin Pharmacokinet; 1985; 10(1):91-100. PubMed ID: 4038635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.